MARKET

ESPR

ESPR

Esperion Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

49.10
-2.74
-5.29%
After Hours: 49.53 +0.43 +0.88% 17:40 01/24 EST
OPEN
51.80
PREV CLOSE
51.84
HIGH
53.16
LOW
48.82
VOLUME
567.40K
TURNOVER
--
52 WEEK HIGH
61.93
52 WEEK LOW
33.13
MARKET CAP
1.34B
P/E (TTM)
-13.2907
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ESPR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ESPR News

  • Biotech Bonanza: 2020 Outlook In An Election Year
  • Seeking Alpha - Article.01/08 21:15
  • The Daily Biotech Pulse: Verastem In-Licenses Chughai's Tumor Drug, Midatech Surges On Positive Study Results
  • Benzinga.01/08 13:12
  • The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering
  • Benzinga.01/07 12:57
  • Esperion to Present at the 38th Annual J.P. Morgan Healthcare Conference
  • GlobeNewswire.01/07 12:30

More

Industry

Biotechnology & Medical Research
-2.64%
Pharmaceuticals & Medical Research
-2.00%

Hot Stocks

Name
Price
%Change

About ESPR

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy.
More

Webull offers Esperion Therapeutics Inc (ESPR) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.